1621090-72-9

Upstream product

• 51-28-5 2,4-Dinitrophenol 
• 459-46-1 4-Fluorobenzyl bromide 
• 1621090-53-6 1-(4-fluorobenzyloxy)-2,4-dinitrobenzene 
• 1621090-60-5 4-(4-fluorobenzyloxy)benzene-1,3-diamine 
• 1621090-66-1 diethyl 4-(4-fluorobenzyloxy)-1,3-phenylenedicarbamate 

Downstream Products

• 1621090-30-9 1-(6-(4-fluorobenzyloxy)quinazolin-7-yl)-3-p-tolylurea 
• 1621090-32-1 1-(3,4-dichlorophenyl)-3-(6-(4-fluorobenzyloxy)quinazolin-7-yl)urea 
• 1621090-33-2 1-(6-(4-fluorobenzyloxy)quinazolin-7-yl)-3-(3-fluorophenyl)urea 
• 1621090-29-6 1-(6-(4-fluorobenzyloxy)quinazolin-7-yl)-3-(4-(trifluoromethyl)phenyl)urea 
• 1621090-31-0 1-(3-chlorophenyl)-3-(6-(4-fluorobenzyloxy)quinazolin-7-yl)urea 
• 1621090-34-3 1-(6-(4-fluorobenzyloxy)quinazolin-7-yl)-3-(2-fluorophenyl)urea 

Relevant academic research and scientific papers

6-Benzyloxyquinazolin-7-ylurea derivatives with an anticancer activity

The present invention relates to a 6-benzyloxyquinazoline-7-ylurea derivative having anticancer activity and, more specifically, to a 6-benzyloxyquinazoline-7-ylurea derivative represented by chemical formula 1 and a compound selected from pharmaceuticall

Novel quinazoline-urea analogues as modulators for Aβ-induced mitochondrial dysfunction: Design, synthesis, and molecular docking study

A novel series of twenty-six quinazoline-urea derivatives was designed and synthesized. Their blocking activities against β-amyloid peptide (Aβ) induced mitochondrial permeability transition pore (mPTP) opening were evaluated by JC-1 assay which measured